LEO Pharma submits NDA to US FDA for aerosol foam to treat plaque psoriasis
The aerosol foam formulation of the fixed combination of calcipotriene and betamethasone dipropionate 0.005%/0.064%, has been developed to improve treatment for patients with plaque psoriasis. The NDA is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.